IMPORTANCE Intravenous acetaminophen is a commonly prescribed analgesic for the prevention and treatment of postsurgical pain. Its efficacy in the context of endoscopic sinus surgery (ESS) has yielded mixed results.
C hronic rhinosinusitis (CRS) is a common inflammatory condition of the nasal cavity and paranasal sinuses that affects an estimated 30 million individuals in the United States. 1, 2 Endoscopic sinus surgery (ESS) is an increasingly prevalent treatment option for patients with CRS whose symptoms are refractory to standard medical treatment. Prior studies [3] [4] [5] have found that ESS provides an effective method to improve disease-specific quality-of-life outcomes by widening the natural sinonasal outflow tracts, improving mucociliary clearance, and optimizing delivery of medical therapy to diseased sites. An estimated 200 000 to 300 000 outpatient ESS procedures are performed annually in the United States, making it among the most common ambulatory surgeries performed. 6, 7 Postoperative pain control has garnered the attention of many major medical societies. Pain assessment and follow-up is recognized by the American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS), for example, as an individual quality measure reportable to the Physician Quality Reporting System (PQRS). 8 The American Pain Society has also identified several research gaps in postoperative pain management, including studies that examine the efficacy of various analgesics according to type of surgery performed. 9 There currently is no consensus regarding optimal pain control after functional endoscopic sinus surgery (FESS) for CRS. Available research indicates that, on average, the pain experienced in the acute postoperative period after FESS is mild; however, some studies cite up to a 70% incidence of pain requiring opioid analgesics in the absence of a nonopioid alternative. 10, 11 Furthermore, opioid analgesic use is still common after FESS. 12 Despite its associated mild pain, unplanned admissions after ESS occur in 2% to 9% of cases, and acute pain remains among the most common causes for readmission. [13] [14] [15] Taken together, the available evidence underscores an apparent mismatch between perceived pain after FESS and its management. While pain associated with FESS is mild, it is not trivial and should be treated; however, employing opioid analgesics in the setting of FESS may be excessive and lead to undue adverse effects. High-quality studies that evaluate the efficacy of alternative, nonopioid regimens are necessary to promote a new standard of care in the management of pain after FESS. Currently, there are limited double-blinded, placebo-controlled studies that evaluate nonopioid analgesics in the postoperative period, and the findings from available studies are mixed. 10, 16, 17 We compared the efficacy of perioperative intravenous acetaminophen (IVAPAP) with placebo in controlling postoperative pain following ESS. A prospective and double-blinded study was conducted to determine whether IVAPAP improved postoperative pain as measured by a patient-reported rating system. We also sought to determine whether perioperative IVAPAP use could reduce postoperative opioid requirements and opioid-related adverse events.
Methods
This was a prospective, double-blinded, single-center, randomized clinical trial conducted as a joint collaboration between the Departments of Anesthesiology and Otorhinolaryngology-Head and Neck Surgery at McGovern Medical School at the University of Texas Health Science Center (UTHSC). The study was registered with the US National Institutes of Health and received approval from the UTHSC at Houston institutional review board. Written informed consent was obtained from all participants prior to their participation in the study and they were not compensated. The study duration was between July 2012 and September 2014. The trial protocol is included in the Supplement.
Patient Selection and Randomized Enrollment
This clinical trial enrolled individuals aged at least 18 years and undergoing planned ESS for medically refractory CRS. Participants underwent a preoperative computed tomography scan of the paranasal sinuses with a navigation protocol and demonstrated objective evidence of CRS. Exclusion criteria included history of hypersensitivity to acetaminophen; known or suspected history of opioid intolerance; a history of chronic pain or use of opioid or any other pain modulator in the previous 2 weeks; end-stage renal disease; end-stage liver disease; severe depression or anxiety; seizure disorder; and known or suspected history of alcohol or drug abuse.
Prior to their surgical procedure, patients were randomly assigned to either the experimental group or placebo group by an investigational pharmacist. In the experimental group, participants received 1000 mg IVAPAP in 100 mL of normal saline during induction of general anesthesia, or about 15 minutes before the start of surgery. In the control group, 100 mL of normal saline was administered. Patients received a second dose 4 hours after the initial dose. The total dose of IVAPAP did not exceed 2000 mg for any patient on the day of surgery. Patients, surgeons, anesthesiologists, and research staff were blinded to the test medications administered at all stages of data acquisition.
Anesthesia and Surgical Protocols
The delivery of anesthesia was standardized for all participants undergoing ESS. All participants were medicated in the preoperative period with dexamethasone sodium phosphate (10 mg), midazolam (1 or 2 mg based on body weight), and either cefazolin or clindamycin (1 g and 600 mg, respectively). Standard intravenous induction of general anesthesia
Key Points
Question Can intravenous acetaminophen given at the time of sinus surgery control postoperative pain better than placebo?
Findings In this prospective, randomized clinical trial including 62 patients undergoing endoscopic sinus surgery for chronic rhinosinusitis, intravenous acetaminophen given within the first hour after surgery was associated with a reduction in pain and this difference may be clinically meaningful.
Meaning Given our inconclusive results and the high cost of intravenous acetaminophen we cannot recommend it as a pain control regimen after sinus surgery.
was provided by the attending anesthesiologists using propofol (2 mg/kg), lidocaine (0.5 mg/kg), and rocuronium (0.5 g/kg). Intraoperatively, patients were monitored by the anesthesiologists using electrocardiography, noninvasive blood pressure monitoring, pulse oximetry, and a temperature probe. Maintenance anesthesia was achieved with 2% sevoflurane and fentanyl citrate (2 μg/kg). Additional doses of fentanyl at 1 μg/kg were administered intraoperatively to patients if their heart rates and blood pressures were greater than 15% to 20% of their expected baseline.
Following induction of general anesthesia, ESS was performed by 1 of 3 fellowship-trained rhinologists. Prior to the surgical start, patients received topical decongestion through the placement of pledgets soaked in oxymetazoline hydrochloride under the middle turbinates bilaterally. Local anesthesia was also provided through the submucosal injection of approximately 3 mL of lidocaine, 1% , with 1:100 000 epinephrine into the medial infundibular wall and sphenopalatine region. Surgical procedures were performed with standard ESS technique, using a combination of both nonpowered instruments and a microdebrider to dissect the sinuses with objective evidence of CRS. Hemostasis was maintained at the end of procedures through the placement of bioresorbable nasal dressings (Nasopore, Stryker Corporation) in the middle meatus. Patients were extubated when they were fully awake and were transferred to the postanesthesia care unit (PACU) for monitoring of vital signs, assessment of pain, and adverse events.
Postoperative Outcome Measurements
Pain measurement was performed using a validated VAS on a 100-mm horizontal line in the manner similar to that used by Church et al. 18 For each VAS measurement, patients were presented with a VAS card and asked to indicate their level of pain from 0 (no pain) to 100 (most severe pain imaginable) by placing a mark on a vertical line corresponding to a numerical value on the VAS scale. A minimum clinically significant change in pain on VAS scale is defined as the minimum difference in millimeters resulting in patients noting "a little more" or "a little less pain" from preceding VAS score. Using patients reporting acute pain from trauma and subsequently validating in a heterogenous group of adult patients presenting to an urban emergency department, a minimum clinically significant change in pain was defined as a change in 13 mm on the VAS scale. [21] [22] [23] After ESS, patients were asked to report their pain at 7 different postoperative time points: 15 minutes, 30 minutes, 45 minutes, 60 minutes, 2 hours, 12 hours, and 24 hours. The VAS pain assessments at 15 minutes, 30 minutes, 45 minutes, 60 minutes, and 2 hours were completed in the PACU, whereas at 12 hours and 24 hours, participants recorded their assessments in a diary that was collected and recorded at their next clinical visit. All adverse events in the immediate postoperative period were also recorded. Adverse events were recorded at each time point as noted above and included, but were not limited to, VAS over 40, hypertension, hypotension, self-reported nausea, emesis, tachycardia, bradycardia, and allergic reaction.
In an effort to evaluate the effectiveness of IVAPAP for postoperative pain control in an intention-to-treat approach, postoperative oral and intravenous opioid requirements were also recorded during the first 24 hours after surgery. In the PACU, morphine was administered intravenously as a rescue analgesic to patients who reported considerable pain; doses of intravenous morphine were repeated at 30-minute intervals until patients indicated that their pain was consistent at only mild intensity. No other analgesic medication was administered during the immediate postoperative period. The total number of doses and total dosage of intravenous morphine were both recorded for each participant, allowing for a comparison of immediate needs for rescue analgesic medication between IVAPAP and control groups. At the time of discharge from the PACU, all participants were provided prescriptions for 500 mg acetaminophen tablets and an oral narcotic (325/5 mg acetaminophen-hydrocodone) tablets. The participants were instructed to take an oral acetaminophen tablet every 6 hours for the first 12 hours after discharge if their VAS pain score exceeded 40. Twelve hours after discharge, participants were instructed to take an oral narcotic every 6 hours if their VAS pain score exceeded 40. Participants were contacted 24 to 48 hours after surgery by research staff and pain as well as the number of acetaminophen-hydrocodone doses taken was recorded.
Statistical Analysis
Power analysis was conducted using the following hypotheses: (1) at the time of arrival in PACU recovery, the incidence of postoperative pain in the control group would be 70%, and (2) the incidence of postoperative pain would be less than 35% in the experimental group. We determined that at least 25 patients in each group should be enrolled to achieve a power of 80%, allowing for a type I error of .05.
For data analysis, continuous variables were summarized by means and standard deviations. Categorical variables were summarized by frequencies and percentages. The differences between 2 treatment groups in terms of demographics, preoperative variables, and intraoperative data were compared using 2 sample t test (or Wilcoxon rank sum test as appropriate for continuous variables) and χ 2 test (or Fisher exact test as appropriate) for categorical variables. Generalized estimating equations was applied to evaluate the treatment effect on VAS collected at 7 different postoperative time points to account for the correlation within patients. Differences in the mean VAS scores with 95% CIs were reported for each time point. 19 All statistical analyses were performed using SAS 9.4 statistical software (SAS Institute, Inc).
Results
A diagram summarizing the study's flow is included ( Figure) . A total of 62 adult participants were enrolled in this prospective study from July 2012 to September 2014. Two patients were excluded owing to a change in the preoperative diagnosis from CRS to a sinonasal mass in 1, and the development of an induction arrhythmia following general anesthesia, not related to the administration of the investigational medication, that prompted the surgery to be cancelled. Thirty-one patients were randomized into the IVAPAP group and 29 patients were randomized into the placebo group. Evaluation of the demographics (Table 1 ) demonstrated that the 2 groups were similar in terms of age, disease phenotype, severity of disease, and intraoperative variables. All 60 randomized patients provided a minimum of 3 VAS pain assessment scores in the immediate postoperative period. No patient experienced significant postoperative complications related to the administration of IVAPAP.
At each of the 3 first time points (15, 30 , and 45 minutes), there were large differences in VAS score between the IVAPAP and placebo groups favoring the IVAPAP group. Furthermore, the upper bound of the CIs around the difference in VAS between the IVAPAP and placebo groups exceeded the clinically meaningful difference of 13, suggesting that the data are compatible with important clinical effects ( Table 2) . [20] [21] [22] [23] For instance, the upper bound of the CI at 45 minutes suggests that the true difference could be as great as 22 mm on the VAS scale. However, at the 1-hour assessment after surgery, the absolute VAS difference (95% CI) was −1.7 (−13.0 to 9.6). Whereas the upper bound of the CI of 13 suggests a clinically significant effect, the point estimate of −1.7 suggests little effect. The width of the CIs at all time points indicates imprecision in the estimate of the effect of IVAPAP, thus preventing any solid conclusion about the effect of IVAPAP compared with placebo.
Importantly, at the 12-and 24-hour time points the absolute differences in VAS score favored the placebo group and inspection of the CIs suggest that a clinically meaningful reduction in pain perception in the placebo group relative to the IVAPAP group is possible. This change in pain at these later time points favoring the placebo group reflects the difference in VAS trend over the 24-hour postoperative time period. The IVAPAP group was characterized by a stable mean VAS score while the placebo group was associated with a decrease in mean VAS score with time, with the most significant drops noted at 12 and 24 hours after the procedure.
There was no significant difference in the number of patients requiring intravenous morphine and oral narcotics. In the PACU, 8 of 31 patients (26%) in the IVAPAP group required supplemental intravenous morphine, whereas 10 of 29 patients (34%) in the placebo group required supplemental intravenous morphine for an absolute reduction in the percentage of participants requiring morphine of 8.7% (95% CI, −14.5% to 31.8%). No participants required hospital admission for observation secondary to any adverse event or other cause. There was no difference in incidence of adverse events between the IVAPAP and placebo group (IVAPAP, 55%; placebo, 55%), yet there was a 7.5% absolute increase (95% CI, −17.1% to 32.0%) in the proportion of patients in the IVAPAP group selfreporting postoperative nausea compared with placebo ( Table 3) .
Discussion
In this study, we found differences in pain perception between IVAPAP and placebo favoring IVAPAP during the first 45 minutes. None of these differences were large enough to be clinically meaningful, although inspection of the 95% CIs around the differences suggest that the true effect of IVAPAP could be clinically meaningful. Importantly, at 12 and 24 hours, pain perception was actually less among the patients in the placebo group than patients in the IVAPAP group and the data are compatible with a clinically meaningful reduction in pain among the placebo group. The wide CI around the difference, the inclusion of the null value for the difference (0) in the CI, and the inclusion of clinically meaningful values for the difference in the CI range makes this an inconclusive study with regards to the primary study question. A recent Cochrane meta-analysis found that intravenous acetaminophen formulations (paracetamol, proparacetamol) were superior to placebo in reducing postoperative pain and reducing opioid consumption, while demonstrating a similar safety profile to that of placebo. 24 The intravenous formulation of acetaminophen has emerged in the United States as an attractive therapeutic agent given its predictable bioavailability and its relatively low adverse effect profile. To date, there have been few studies which investigate the efficacy of IVAPAP in controlling postoperative pain after ESS, the results of which have been mixed. b Indicates the difference in percentage between 2 groups as well as its 95% CI.
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and compared the efficacy of IVAPAP vs placebo given immediately after surgery in reducing postoperative pain in patients undergoing FESS. The authors found that a single 1 g dose of IVAPAP given postoperatively was effective at reducing maximum pain experienced for the first 3 hours after surgery, with a significant difference in mean numeric rating score for pain at 2 hours. Total rescue opioid consumption use was reduced in the experimental group, but this did not result in reduction in opioid-related adverse events. In another study, Koteswara et al 17 designed a randomized, double-blind study of 39 patients undergoing ESS to compare the preoperative and postoperative pain control related to the administration of 1 g of paracetamol. This study found a significant reduction in numeric pain score rating and amount of rescue opioid use in patients receiving preemptive doses of paracetamol. Similar to other studies, no differences in adverse events were noted. This study included only a limited description of the clinical characteristics of patients enrolled in the study. Observation of the changes of the mean VAS score over the first 24 postoperative hours shows a relatively stable report of pain with intravenous acetaminophen. However, the placebo group reported a higher mean VAS score immediately after surgery, which decreased over the 24 postoperative hours resulting ultimately in a clinically meaningful difference in VAS score noted at both 12 and 24 hours after surgery. Similar differences in the trends in the mean VAS score over time were noted by Kemppainen et al 10 when study medication was given immediately after FESS. Given the subjectivity of pain assessment, this trend in VAS score over time may suggest that IVAPAP stabilizes pain and minimizes spikes in postoperative pain, but it also may suggest that IVAPAP can prevent expected reduction in postoperative pain over time. This study is unable to differentiate between these 2 possibilities.
Limitations
There are several limitations of this study, including low precision and incomplete and missing data from patients after discharge. The low precision, as demonstrated by the wide CIs, associated with the primary outcome measure VAS score and the secondary outcome measures, undermines the ability to make definitive conclusions from the data. In addition, the incomplete and missing data from patients after discharge limits conclusion at these later time points. Despite the study's limitations and its inconclusive results, inspection of the CIs highlight salient points regarding the value of intravenous acetaminophen in FESS. Acetaminophen may be effective in treating early postoperative pain, thus avoiding opioids and other narcotics. Although this study evaluated the effects of intravenous acetaminophen, the results warrant a study with oral acetaminophen. At the time of preparing this manuscript, intravenous acetaminophen was protected by patent. At approximately US $12 per unit, the associated costs of intravenous acetaminophen make it considerably more expensive than alternative analgesics. 25 Although we did not conduct a cost analysis as part of our study, the value of intravenous acetaminophen in managing postoperative pain after FESS seems limited and alternative strategies, especially those with reduced associated cost, should be considered.
Conclusions
In this randomized clinical trial, we observed reduction in pain in the IVAPAP group relative to the placebo control in the first postoperative hour and the upper bound of the CI around this difference suggests a clinically meaningful difference is possible. Yet, the wide CI around the observed pain difference and the inclusion of the null value prevents definitive conclusions. The use of IVAPAP was associated with a reduction in postoperative opioid requirements but the inclusion of the null value in the CI and the wide CI also prevents definitive conclusions. Given the high cost of IVAPAP and inconclusive results, we cannot recommend its use for the control of perioperative pain reduction after ESS. Rarely, however, have we asked if we are overtreating pain. Certainly patients will take only the medication they need, and what's the harm with a few unused pills? Furthermore, are we not better off prescribing beyond the likely needs of our patients to ensure their comfort and minimize postoperative phone calls?
The United States is in the midst of an opioid epidemic. From 2000 to 2015, more than half a million people died from drug overdoses and opioids are implicated in most cases. 1 Every day 91 Americans die from an opioid overdose. 2 There is a clear relationship between opioid prescriptions and opioidrelated overdose deaths. Since 1999, both total opioid prescriptions 3 and deaths from prescription opioids 2 have quadrupled. The victims of opiate overdose are often not the recipients of opioid prescriptions. Most patients do not dispose of unused opioid medications and rarely are these maintained in locked or secure locations. 4 Adolescents and adults who use opioids for nonmedical reasons frequently report obtaining these medications from family and friends, 5 and 20% of patients with unused prescriptions describe sharing their leftover opioids. 4 The first CDC recommendation for preventing opioid deaths focuses on improving opioid prescribing patterns. 4 Well-designed studies establishing the use of nonopioid pain medication in the perioperative setting are critical for limiting postoperative opioid prescriptions and improving our prescribing patterns. In this issue, Tyler et al 6 have initiated this effort with a prospective, double-blinded randomized trial investigating the impact of intravenous acetaminophen during endoscopic sinus surgery. While the overall results of this study are inconclusive, the authors do identify a trend toward diminished immediate postoperative pain and opioid requirements in the intravenous acetaminophen group. These results should serve to increase awareness of the options available for perioperative pain management during endoscopic sinus surgery. Just as importantly, the authors highlight the apparent mismatch between perceived pain following endoscopic sinus surgery and current perioperative pain management practices. As we explore nonopioid pain management protocols for perioperative treatment with endoscopic sinus surgery, timing and route of medication administration as well as mechanism of action should be considered. While intravenous acetaminophen may have promise in this area, oral or rectal administration could provide similar benefit with considerable cost savings. Nonsteroidal anti-inflammatory (NSAID) medications should also be considered. Traditionally, we have 
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Background and Rationale
Unrelieved postoperative pain may result not only in suffering and discomfort, but may also lead to multiple physiological and psychological consequences, which can contribute to adverse perioperative outcomes. Inadequate perioperative analgesia can potentially contribute to a higher incidence of myocardial ischemia. Additionally, the use of opioids has been associated with major side effects that can include impaired wound healing and delayed gastrointestinal (GI) motility that results in prolonged postoperative ileus. Pain and other postoperative and postanesthetic complications, directly related to surgery or to the analgesic (nausea, vomiting, headache) can potentially disturb the patient and prolong time to discharge.
Patients in ambulatory settings are especially affected if and when postoperative complications do occur. Multimodal (or, balanced) analgesia represents an increasingly popular approach to preventing postoperative pain. This approach involves administering a combination of opioid and non-opioid analgesics. Nonopioid analgesics are increasingly being used as adjuvants before, during, and after surgery to facilitate the recovery process after ambulatory surgery 1 . Early studies evaluating approaches to facilitating the recovery process have demonstrated that the use of multimodal analgesic techniques can improve early recovery as well as other clinically meaningful outcomes after ambulatory surgery 2, 3 . Acetaminophen (APAP), named paracetamol outside the United States, has been available as an analgesic and antipyretic agent in the United States and the United Kingdom since the 1950s. Currently, APAP is the most commonly prescribed analgesic and antipyretic in children and is indicated for the short-term management of mild-to-moderate pain and the reduction of fever in both children and adults. In the United States, APAP has until recently only been available as oral and rectal preparations. As such, the use of this therapy in post-operative or acute care setting is hampered because of variability in analgesic effect and time of onset using these routes of administration 4, 5 . Intravenous APAP is considered as the non-opioid analgesic of choice to treat postoperative mild and moderate pain, and has been demonstrated in several randomized trials to be both safe and effective at reducing acute post-operative pain in both children and adults 6 . Furthermore, in the treatment of severe pain, it can reduce the need for opioid-analgesics while exhibiting a relatively limited side effect profile when compared to opiods and nonsteroidal anti-inflammatory drugs 7 .
Chronic rhinosinusitis (CRS) describes a group of disorders characterized by inflammation of the nasal mucosa and/or paranasal sinuses for at least 12 consecutive weeks 8, 9, 10 .
In the United States, CRS affects approximately 30 million people, and represents 2% of the primary diagnoses in physician office visits, resulting in an estimated 200,000 sinus procedures annually 11 . Patients suffering from CRS that is refractory to medical management complain of symptoms that include fatigue, headache, nasal drainage, facial pain and pressure, and decreased sense of smell 12 . Functional endoscopic sinus surgery (FESS) represents a surgical approach to treating CRS that is unresponsive to medical management. Outcomes studies have identified FESS as efficacious at reducing the majority of symptoms related to CRS 13, 14 . Despite this, pain associated with CRS remains a significant co-morbidity that often is resistant to both medical and surgical management 14 . Reducing the incidence and severity of acute post-operative pain is paramount to reducing the development of chronic pain that may exacerbate a patient's existing pain 15, 16, 17 . The use of pre-and intra-operative IV acetaminophen thus serves as a unique pain management modality in this setting, as it has the potential for reducing post-operative complications and pain, with the additional benefit of minimal intraoperative bleeding, an undesirable complication often associated with FESS 18 and with the use of NSAIDs 19,20. The use of IV acetaminophen in ENT surgery is not a novel endeavor. Indeed, studies have demonstrated the efficacy and safety of IV acetaminophen for use in tonsillectomy and FESS 21, 22 . We wish to provide a more comprehensive analysis of pain management in the setting of FESS in the following ways : 1.) by administering IV acetaminophen perioperatively (before start of surgery, and after surgery completion; 2.) employ a pain score of 4 (whereas other studies use 3) as a cutoff for breakthrough pain; and, 3.) address novel outcomes including patient sedation and patient satisfaction, in addition to opioid analgesic use. In our institution, we have completed a preliminary pilot study exploring the use of intravenous anesthesia which included acetaminophen during bilateral endoscopic sinus surgery. Secondary outcomes measured during the study included:
Rescue analgesic use 3.
Nausea/Vomiting 4.
Time spent in recovery 5.
Successful discharge from the PACU and the Hospital
Our pilot data has reaffirmed that the procedure is overall benign, with few associated risks and adverse events. Of note, none of the patients in our preliminary study required admission to the hospital after surgery for further observation as a result of uncontrolled pain or nausea. Based on this experience, we would like to explore the efficacy of intravenous acetaminophen (Ofirmev), a non opioid/non steroidal analgesic, in endoscopic sinus surgery.
Objectives
In this study, we wish to formally investigate the effects of IV acetaminophen (Ofirmev) administered perioperatively and during endoscopic sinus surgery on pain experienced and on the use of opioid analgesics. Secondarily, we wish to collect data on spontaneous reports of adverse events (AEs) and overall patient satisfaction.
Specific Aims
Primary aim: Assess the efficacy of IV acetaminophen in controlling postoperative painWe hypothesize that the use of IV acetaminophen before and after FESS will reduce post operative pain by approximately fifty percent in selected patients. The incidence and intensityof pain will be assessed using a visual analog scale, or VAS, (0-100; 0 = no pain; 100 = worst pain) before (baseline) and after surgery. Each patient's baseline pain intensity will be evaluated on the day of surgery in the preoperative waiting area. Postoperative pain intensity will be measured using VAS in the postoperative anesthesia care unit different time points -0 minutes; 15 minutes; 30 minutes; 1 hour; 2 hours; 3 hours; 4 hours postoperatively.
Secondary aims

Secondary aim 1: Investigate the effect of IV acetaminophen on the use of postoperative opioid analgesics
We hypothesize that greater pain control using IV acetaminophen will result in a decreased need for postoperative opioid analgesics. The total amount of postoperative opioid use will be recorded as follows: after the patient has arrived in the PACU (post anesthesia care unit), the incidence and intensity of pain will be assessed using a VAS (0-100) as described above . Pain relief will be achieved by incremental doses of morphine 1 mg bolus, based on a VAS score of 4 and above, to be repeated every 5 minutes if needed. The total amount of morphine utilized in PACU and time of 2 nd dose of IV acetaminophen will be recorded.
Secondary aim 2: Analyze effects of IV acetaminophen on intraoperative analgesic use
Brief episodes of tachycardia and hypertension are expected in FESS procedures. These will be treated by increasing inhalational agents of 0.5% inspired fraction at a time. A supplemental dose of fentanyl in the amount of 1 mcg/kg will be available for HR and BP greater than 15-20% above baseline after no response to volatile change. The following measurements will be recorded: total amount of fentanyl utilized; the hemodynamic parameters during surgery and anesthesia; the inspired fraction of inhalational agent; and the number of step-wise increases for hemodynamic control. Differences between control and experimental groups will be analyzed for statistical significance.
Secondary aim 3: Identify potential correlation between vital signs and postoperative pain intensity
We wish to evaluate if postoperative pain intensity is associated with changes in vital signs, such as heart rate, respiratory rate, blood pressure, and temperature. Each patient's vital signs will be collected at the specified time points as outlined above, in addition to measuring pain intensity using the VAS scale. Data will be collected and analyzed to search for a statistical correlation between postoperative pain intensity and vital sign changes (e.g., increased respiratory rate correlates with greater pain intensity). In addition, differences in vital signs between groups will be analyzed for statistically significant differences.
Specific am 4: Examine the effect of IV acetaminophen on post-operative quality of recovery
In this study, we will analyze the post-operative quality of recovery by researching three different factors: 1.) the number of spontaneous reported adverse events; 2.) the level of postoperative sedation; and, 3.) the patient's overall reported satisfaction with hospital experience.
We will monitor and record any adverse events including, but not limited to, dizziness, nausea, vomiting, tachycardia, bradycardia, arrhythmia, hypertension, hypotension, allergic reaction, in addition to any other complaint from the patient.
Sedation will be assessed using a 4-point scale, with 3 = sleeping, not arousable; 2 = sleeping, arousable; 1 = awake but drowsy; 0 = fully awake. Each assessment will be conducted every 10 minutes for the first hour, and then every 30 minutes until time of discharge.
A questionnaire evaluating pre-discharge quality and efficacy of pain management will be given to the patient before discharge. A telephone interview and questionnaire will be administered within 48 hours but ideally 24-30 hrs from discharge to assess for pain control, utilization of analgesics, and patient satisfaction. The follow-up questionnaire will be tailored to discriminate overall experience but differentiating immediate postoperative pain control versus control of pain at home.Hypothesis The use of IV acetaminophen (Ofirmev) is both safe and efficacious in reducing post-operative pain; we hypothesize that its use will reduce post-operative pain by 50% when compared to control group using the VAS analog pain scoring system.
Study Design
Study design type: Double blind, prospective randomized controlled study at a single institution Study groups: A total of 60 patients will be enrolled in the study. 30 patients will be randomized to the control group, and 30 will be randomized to the experimental treatment group.
Experimental group: The experimental group will receive a preoperative dose of 1000mg IV acetaminophen over 15 minutes. This will occur at least 15 minutes before the start of surgery and no earlier than 1 hour before the start of surgery. Another 1000mg dose of IV acetaminophen will be administered 4 hours after the first dose. Patients will be discharged with instruction to continue APAP 500 mg PO every 6-8 hours. A rescue analgesic containing oxycodone will also be provided (with APAP concentrations of 325 mg per Hospital and FDA recommendations). Patients will be instructed verbally and by a written note, not to exceed a total 4grams of acetaminophen per day, total dose includes both IV and PO intake. A safety explanation pamphlet will be provided to the patient and accompanying family members or significant others, with the written instructions about the 4 grams limits of APAP per day.
Control group: The control group will receive 100 mL of 0.9% normal saline in place of IV acetaminophen in the same manner as the experimental group; the investigator/physician in question will be blinded to the agent that is being administered. Patients will be discharged with instruction to continue APAP 500 mg PO every 6-8 hours. A rescue analgesic containing oxycodone will also be provided (with APAP concentrations of 325 mg per Hospital and FDA recommendations). Patients will be instructed verbally and by a written note, not to exceed a total 4 grams of acetaminophen per day, total dose includes both IV and PO intake. A safety explanation pamphlet will be provided to the patient and accompanying family members or significant others, with the written instructions about the 4 grams limits of APAP per day.
Protocol: Patients scheduled for FESS that meet inclusion and exclusion criteria will be approached in the ENT clinic at the time that the patient is being scheduled for surgery. The typical procedure lasts an average of 3 hours and the average recovery time (phase and phase 2 PACU combined) is 3-4 hours before discharge. Patients and family members or significant others will be notified about the study and the consent will be reviewed. If the patient wishes to proceed with enrollment, a consent form will be signed. At that time, a preoperative
